Temozolomide does not influence the transcription or activity of matrix metalloproteinases 9 and 2 in glioma cell lines

Journal of Clinical Neuroscience

Volumn 41, Issue , 2017, Pages 144-149

  Suzuki, Yuta ^a   Fujioka, Kouki ^a   Ikeda, Keiichi ^a   Murayama, Yuichi ^a   Manome, Yoshinobu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glioblastoma; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Semi quantitative reverse transcription PCR; Temozolomide

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; ZYMOGRAPHY; ANALOGS AND DERIVATIVES; CELL MOTION; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; DACARBAZINE; GLIOBLASTOMA; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; TRANSCRIPTION, GENETIC;

EID: 85017396189     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2017.03.048     Document Type: Article

References (61)

1. Furnari, F.B., Fenton, T., Bachoo, R.M., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21 (2007), 2683–2710.
2. Walker, M.D.A.E. Jr, Hunt, W.E., MacCarty, C.S.M.M.M.M. Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 49 (1978), 333–343.
3. Stevens, M.F.G., Hickman, J.A., Langdon, S.P., et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5, 1-d]-1, 2, 3, 5-tetrazin-4 (3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47 (1987), 5846–5852.
4. Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352 (2005), 987–996.
5. Patel, M., McCully, C., Godwin, K., et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61 (2003), 203–207.
6. Ostermann, S., Csajka, C., Buclin, T., et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10 (2004), 3728–3736.
7. D'Atri, S., Piccioni, D., Castellano, A., et al. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 6 (1995), 389–393.
8. Newlands, E.S., Stevens, M.F., Wedge, S.R., et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23 (1997), 35–61.
9. Roos, W.P., Kaina, B., DNA damage-induced cell death by apoptosis. Trend Mol Med 12 (2006), 440–450.
10. Yoshii, Y., Maki, Y., Tsuboi, K., et al. Estimation of growth fraction with bromodeoxyuridine in human central nervous system tumors. J Neurosurg 65 (1986), 659–663.
11. Johnson, D.R., O'Neill, B.P., Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107 (2012), 359–364.
12. Hegi, M.E., Diserens, A.-C.C., Gorlia, T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 352 (2005), 997–1003.
13. Matsukado, Y., Maccarty, C.S., Kernohan, J.W., The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 18 (1961), 636–644.
14. Tran, B., Rosenthal, M.A., Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17 (2010), 417–421.
15. Liotta, L.A., Tumor invasion and metastases–role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 46 (1986), 1–7.
16. Rao, J.S., Steck, P.A., Mohanam, S., et al. Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Res 53 (1993), 2208–2211.
17. Gross, J., Lapiere, C.M., Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci 48 (1962), 1014–1022.
18. Demuth, T., Berens, M.E., Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 70 (2004), 217–228.
19. Stetler-Stevenson, W.G., Liotta, L.A., Kleiner, D.E., Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7 (1993), 1434–1441.
20. Egeblad, M., Werb, Z., New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002), 161–174.
21. Rao, J., Steck, P., Tofilon, P., et al. Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro Matrigel model. J Neurooncol 18 (1993), 129–138.
22. Sawaya, R.E., Yamamoto, M., Gokaslan, Z.L., Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14 (1996), 35–42.
23. Kachra, Z., Beaulieu, E., Delbecchi, L., et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 17 (1999), 555–566.
24. Forsyth, P.A., Laing, D.T., Gibson, A.W., et al. High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. J Neurooncol 36 (1998), 21–29.
25. Hagemann, C., Anacker, J., Ernestus R-II, Vince GH. A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World. J Clin Oncol 3 (2012), 67–79.
26. Manome, Y., Datta, R., Fine, H.A., Early response gene induction following DNA damage in astrocytoma cell lines. Biochem Pharmacol 45 (1993), 1677–1684.
27. Dosch, J., Kaina, B., Induction of c-fos, c-jun, junB and junD mRNA and AP-1 by alkylating mutagens in cells deficient and proficient for the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) and its relationship to cell death, mutation induction and chromosomal instability. Oncogene 13 (1996), 1927–1935.
28. Caporali, S., Falcinelli, S., Starace, G., et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 66 (2004), 478–491.
29. Caporali, S., Levati, L., Graziani, G., et al. NF-kappaB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. J Transl Med, 10, 2012, 252.
30. Bouchard, F., Bélanger, S.D., Biron-Pain, K., et al. EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth. Blood 116 (2010), 759–766.
31. den Steen, V.P.E., Dubois, B., Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37 (2002), 375–536.
32. Nakabayashi, H., Shimizu, K., Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer, 12, 2012, 453.
33. Kondraganti, S., Mohanam, S., Chintala, S.K., et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res, 2000.
34. Jiang, L., Wu, J., Yang, Y., et al. Bmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathway. BMC Cancer, 12, 2012, 406.
35. Funamizu, N., Lacy, C.R., Fujita, K., et al. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS ONE, 7, 2012, e37424.
36. Giard, D.J., Aaronson, S.A., Todaro, G.J., et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51 (1973), 1417–1423.
37. Coussens, L.M., Fingleton, B., Matrisian, L.M., Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (New York, NY) 295 (2002), 2387–2392.
38. Overall, C.M., López-Otín, C., Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2 (2002), 657–672.
39. Rao, J.S., Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3 (2003), 489–501.
40. Curran, S., Murray, G.I., Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189 (1999), 300–308.
41. Cuzner, M.L., Opdenakker, G., Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 94 (1999), 1–14.
42. Chakraborti, S., Mandal, M., Das, S., et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253 (2003), 269–285.
43. Brown, G.T., Murray, G.I., Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol 237 (2015), 273–281.
44. Strongin, A.Y., Collier, I., Bannikov, G., et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270 (1995), 5331–5338.
45. Visse, R., Nagase, H., Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circ Res 92 (2003), 827–839.
46. Deryugina, E.I., Bourdon, M.A., Reisfeld, R.A., et al. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 58 (1998), 3743–3750.
47. Nakada, M., Nakamura, H., Ikeda, E., et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 154 (1999), 417–428.
48. Komatsu, K., Nakanishi, Y., Nemoto, N., et al. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol 21 (2004), 105–112.
49. Vandooren, J., Van den Steen, P.E., Opdenakker, G., Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 48 (2013), 222–272.
50. Shaulian, E., Karin, M., AP-1 as a regulator of cell life and death. Nat Cell Biol 4 (2002), e131–e136.
51. Gilmore, T.D., Introduction to NF-κB: players, pathways, perspectives. Oncogene 25 (2006), 6680–6684.
52. Cheng, J.C., Chou, C.H., Kuo, M.L., et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25 (2006), 7009–7018.
53. Sukhatme, V.P., Cao, X., Chang, L.C., et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 53 (1988), 37–43.
54. Thiel, G., Cibelli, G., Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193 (2002), 287–292.
55. Shin, S.Y., Kim, J.H., Baker, A., et al. Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor alpha. Mol Cancer Res: MCR 8 (2010), 507–519.
56. Manome, Y., Kunieda, T., Wen, P.Y., et al. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 9 (1998), 1409–1417.
57. Levin, V.A., Phuphanich, S., Yung, W.K., et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 78 (2006), 295–302.
58. Groves, M.D., Puduvalli, V.K., Hess, K.R., et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20 (2002), 1383–1388.
59. Pozzi, A., LeVine, W.F., Gardner, H.A., Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21 (2002), 272–281.
60. Toth, M., Bernardo, M.M., Gervasi, D.C., et al. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem 275 (2000), 41415–41423.
61. Yong, W.V., Power, C., Forsyth, P., et al. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2 (2001), 502–511.